Terms ending in 2028
Every in-force patent on Genentech, Inc.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,008,401 | Multispecific Antibodies In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 7,892,544 | Humanized Anti-Beta-Amyloid Antibody In force · High confidence | Ac Immune S.A. | In force | High confidence | |
| US 8,853,199 | Hydroxylated and Methoxylated Pyrimidyl Cyclopentanes as Akt Protein Kinase Inhibitors In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 7,915,390 | ANTI-NOTCH3 Agonist Antibodies and Their Use in the Treatment of NOTCH3-RELATED Diseases In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 7,888,352 | Phosphoinositide 3-Kinase Inhibitor Compounds and Methods of Use In force · High confidence | F. Hoffmann-La Roche AG | In force | High confidence | |
| US 9,970,043 | Process for Producing Optically Active 2-Alkyl-1,1,3-Trialkoxycarbonylpropane In force · Medium confidence | Genentech, Inc. | In force | Medium confidence | |
| US 10,385,405 | Gene Expression Markers of Tumor Resistance to HER2 Inhibitor Treatment In force · Medium confidence | Genentech, Inc. | In force | Medium confidence | |
| US 9,585,956 | Polynucleotides Encoding Anti-Amyloid Beta Monoclonal Antibodies In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 8,846,683 | Pyrimidyl Cyclopentanes as Akt Protein Kinase Inhibitors In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 9,409,886 | Pyrimidyl Cyclopentanes as Akt Protein Kinase Inhibitors In force · High confidence | Genentech, Inc. | In force | High confidence | |
| 31 more term ends in 2028 · Pro | |||||
10 of 41 patents shown. Soonest term end first, then patent number.
Pro members see all 41, including 6 expiring within the 18 months from Nov 17, 2026.
35 of these are in force and held by Genentech, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.